title: Should we disclose amyloid imaging results to cognitively normal individuals?
abstract: Demonstration of brain accumulation of fibrillar amyloid beta protein via positron emission tomography (PET) with amyloid specific ligands may support the diagnosis of Alzheimer's disease (AD). There is increasing recognition of the potential use of amyloid imaging to detectin vivothe pathology of AD in individuals with no ostensible cognitive impairment. Research use of amyloid PET in cognitively normal patients will be key to pursuit of therapies able to delay cognitive impairment and dementia due to AD. We review the pros and cons of disclosing amyloid imaging results to cognitively normal individuals in clinical and research settings and provide draft recommendations.
authors.affiliation: Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, UCLA David Geffen School of Medicine.
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Grill
authors.affiliation: University of Kansas Alzheimer's Disease Center.
authors.forename: David K
authors.initials: DK
authors.lastname: Johnson
authors.affiliation: University of Kansas Alzheimer's Disease Center.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Burns
keywords: Alzheimer's disease; amyloid PET; disclosure; ethics